The 5-HT Receptor As the Target of Ditans in Migraine - from Bench to Bedside

Overview

Journal Nat Rev Neurol

Specialty Neurology

Date 2023 Jul 12

PMID 37438431

Authors

Dimos D Mitsikostas

Christian Waeber

Margarita Sanchez-Del-Rio

Bianca Raffaelli

Hakan Ashina

Antoinette Maassen Van Den Brink

Anna Andreou

Patricia Pozo-Rosich

Alan Rapoport

Messoud Ashina

Michael A Moskowitz

Affiliations

Soon will be listed here.

Abstract

Migraine is a leading cause of disability in more than one billion people worldwide, yet it remains universally underappreciated, even by individuals with the condition. Among other shortcomings, current treatments (often repurposed agents) have limited efficacy and potential adverse effects, leading to low treatment adherence. After the introduction of agents that target the calcitonin gene-related peptide pathway, another new drug class, the ditans - a group of selective serotonin 5-HT receptor agonists - has just reached the international market. Here, we review preclinical studies from the late 1990s and more recent clinical research that contributed to the development of the ditans and led to their approval for acute migraine treatment by the US Food and Drug Administration and the European Medicines Agency.

Citing Articles

Critical reflections on medication overuse headache in patients with migraine: An unsolved riddle in nociception.

Chiarugi A, Buonvicino D Neurobiol Pain. 2025; 17:100179.

PMID: 40040782 PMC: 11876746. DOI: 10.1016/j.ynpai.2025.100179.

Shared Genetics of Migraine and Gastrointestinal Disorders Implicates Underlying Neurologic Mechanisms Yet Heterogeneous Etiologies.

Chasman D, Guo Y, Chan A, Rist P, Staller K Neurol Genet. 2024; 10(6):e200201.

PMID: 39677849 PMC: 11637577. DOI: 10.1212/NXG.0000000000200201.

Hallmarks of primary headache: part 1 - migraine.

Raggi A, Leonardi M, Arruda M, Caponnetto V, Castaldo M, Coppola G J Headache Pain. 2024; 25(1):189.

PMID: 39482575 PMC: 11529271. DOI: 10.1186/s10194-024-01889-x.

Continuing evolution of migraine-specific therapies - targeting migraine with precision and persistence.

Mitsikostas D, Rapoport A Nat Rev Neurol. 2024; 20(11):645-646.

PMID: 39375562 DOI: 10.1038/s41582-024-01026-x.

[Management of migraine by hospital emergency departments: a retrospective observational study carried out at the Hospital Universitario Virgen del Rocio].

Sanchez-Rodriguez N, Millan-Vazquez M, Fernandez-Panadero A, Gomez-Caminero A, Gonzalez-Oria C Rev Neurol. 2024; 79(6):155-160.

PMID: 39267401 PMC: 11469100. DOI: 10.33588/rn.7906.2024095.

References

Mitsikostas D, Ashina M, Craven A, Diener H, Goadsby P, Ferrari M . European Headache Federation consensus on technical investigation for primary headache disorders. J Headache Pain. 2016; 17:5. PMC: 4747925. DOI: 10.1186/s10194-016-0596-y. View

Ashina S, Terwindt G, Steiner T, Lee M, Porreca F, Tassorelli C . Medication overuse headache. Nat Rev Dis Primers. 2023; 9(1):5. DOI: 10.1038/s41572-022-00415-0. View

Diener H, Antonaci F, Braschinsky M, Evers S, Jensen R, Lainez M . European Academy of Neurology guideline on the management of medication-overuse headache. Eur J Neurol. 2020; 27(7):1102-1116. DOI: 10.1111/ene.14268. View

Deligianni C, Vikelis M, Mitsikostas D . Depression in headaches: chronification. Curr Opin Neurol. 2012; 25(3):277-83. DOI: 10.1097/WCO.0b013e328352c416. View

Caponnetto V, Deodato M, Robotti M, Koutsokera M, Pozzilli V, Galati C . Comorbidities of primary headache disorders: a literature review with meta-analysis. J Headache Pain. 2021; 22(1):71. PMC: 8278743. DOI: 10.1186/s10194-021-01281-z. View

Moskowitz M, Reinhard Jr J, Romero J, Melamed E, Pettibone D . Neurotransmitters and the fifth cranial nerve: is there a relation to the headache phase of migraine?. Lancet. 1979; 2(8148):883-5. DOI: 10.1016/s0140-6736(79)92692-8. View

Ashina M, Hansen J, Do T, Melo-Carrillo A, Burstein R, Moskowitz M . Migraine and the trigeminovascular system-40 years and counting. Lancet Neurol. 2019; 18(8):795-804. PMC: 7164539. DOI: 10.1016/S1474-4422(19)30185-1. View

Pietrobon D, Moskowitz M . Pathophysiology of migraine. Annu Rev Physiol. 2012; 75:365-91. DOI: 10.1146/annurev-physiol-030212-183717. View

Mitsikostas D, Del Rio M . Receptor systems mediating c-fos expression within trigeminal nucleus caudalis in animal models of migraine. Brain Res Brain Res Rev. 2001; 35(1):20-35. DOI: 10.1016/s0165-0173(00)00048-5. View

10.

Andreou A, Holland P, Goadsby P . Activation of iGluR5 kainate receptors inhibits neurogenic dural vasodilatation in an animal model of trigeminovascular activation. Br J Pharmacol. 2009; 157(3):464-73. PMC: 2707992. DOI: 10.1111/j.1476-5381.2009.00142.x. View

11.

Andreou A, Holland P, Lasalandra M, Goadsby P . Modulation of nociceptive dural input to the trigeminocervical complex through GluK1 kainate receptors. Pain. 2015; 156(3):439-450. PMC: 7611087. DOI: 10.1097/01.j.pain.0000460325.25762.c0. View

12.

Mitsikostas D, Del Rio M, Waeber C, Moskowitz M, Cutrer F . The NMDA receptor antagonist MK-801 reduces capsaicin-induced c-fos expression within rat trigeminal nucleus caudalis. Pain. 1998; 76(1-2):239-48. DOI: 10.1016/s0304-3959(98)00051-7. View

13.

Mitsikostas D, Del Rio M, Waeber C, Huang Z, Cutrer F, Moskowitz M . Non-NMDA glutamate receptors modulate capsaicin induced c-fos expression within trigeminal nucleus caudalis. Br J Pharmacol. 1999; 127(3):623-30. PMC: 1566054. DOI: 10.1038/sj.bjp.0702584. View

14.

Goadsby P, Holland P, Martins-Oliveira M, Hoffmann J, Schankin C, Akerman S . Pathophysiology of Migraine: A Disorder of Sensory Processing. Physiol Rev. 2017; 97(2):553-622. PMC: 5539409. DOI: 10.1152/physrev.00034.2015. View

15.

Durham P, Sharma R, Russo A . Repression of the calcitonin gene-related peptide promoter by 5-HT1 receptor activation. J Neurosci. 1998; 17(24):9545-53. PMC: 6573409. View

16.

Amrutkar D, Ploug K, Hay-Schmidt A, Porreca F, Olesen J, Jansen-Olesen I . mRNA expression of 5-hydroxytryptamine 1B, 1D, and 1F receptors and their role in controlling the release of calcitonin gene-related peptide in the rat trigeminovascular system. Pain. 2012; 153(4):830-838. DOI: 10.1016/j.pain.2012.01.005. View

17.

Ferrari M, Goadsby P, Roon K, Lipton R . Triptans (serotonin, 5-HT1B/1D agonists) in migraine: detailed results and methods of a meta-analysis of 53 trials. Cephalalgia. 2002; 22(8):633-58. DOI: 10.1046/j.1468-2982.2002.00404.x. View

18.

Thorlund K, Toor K, Wu P, Chan K, Druyts E, Ramos E . Comparative tolerability of treatments for acute migraine: A network meta-analysis. Cephalalgia. 2016; 37(10):965-978. DOI: 10.1177/0333102416660552. View

19.

Ishida T, Hirata K, Sakoda T, Kawashima S, Akita H, Yokoyama M . Identification of mRNA for 5-HT1 and 5-HT2 receptor subtypes in human coronary arteries. Cardiovasc Res. 1999; 41(1):267-74. DOI: 10.1016/s0008-6363(98)00162-x. View

20.

Phebus L, Johnson K, Zgombick J, Gilbert P, Van Belle K, Mancuso V . Characterization of LY344864 as a pharmacological tool to study 5-HT1F receptors: binding affinities, brain penetration and activity in the neurogenic dural inflammation model of migraine. Life Sci. 1997; 61(21):2117-26. DOI: 10.1016/s0024-3205(97)00885-0. View